Overview
LENZ market data
Price History
LENZ price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.85 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.95 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -519.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.68 – $50.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $144.5M · P/B 1.76 · P/S 6.89.
Company News
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7Benzinga · Aug 12, 2026, 4:24 PM
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · Aug 11, 2026, 9:06 PM
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M EstimateBenzinga · Aug 11, 2026, 8:12 PM
LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth PlatformBenzinga · Jul 6, 2026, 12:25 PM
8-K filing — LENZ Therapeutics, Inc. (LENZ)SEC EDGAR · Jul 2, 2026, 9:00 PM
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: AnalystBenzinga · Jun 24, 2026, 5:45 PM
LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New ZealandBenzinga · Jun 24, 2026, 12:40 PM